The Boulder Bioscience oral drug product candidate (BR9001) is protected by an issued US patent with additional pending international patents. The issued patent runs through 2035. In addition, Boulder BioScience has recently filed two additional patents covering new uses of the API in Acute Ischemic Stroke (AIS) and Traumatic Brain Injury (TBI). Patent application protects a new intravenous drug product (BR4044) for treatment of AIS and TBI with particular use in conjunction with endovascular therapy and thrombectomy. The recently filed patents will run through 2040 and 2042. The recent patent applications claims highly relevant API activity for neuroprotection and inhibition of brain damaging neutrophil activation and NETosis. Inventors, Dr. Michael Zeligs and Dr. Irwin Jacobs, have worked together for over 20 years initiating the GMP production and clinical evaluation of the API. This collaboration has resulted in multiple generations of patented formulation technology for the current API and for similar, poorly soluble APIs, which increase bioavailability and enable therapeutic uses. Contact Boulder BioScience, LLC, for information – [email protected].